Avicularin suppresses cartilage extracellular matrix degradation and inflammation via TRAF6/MAPK activation

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Osteoarthritis (OA) is a degenerative joint disease marked by inflammation and cartilage damage.
• Tumor necrosis factor receptor-associated factor 6 (TRAF6) plays a significant role in OA pathogenesis.

Purpose of the Study:

• To investigate avicularin's protective effects on cartilage extracellular matrix (ECM) degradation and inflammation in OA.
• To explore avicularin's mechanism of action involving the TRAF6/MAPK pathway.

Main Methods:

• In vitro studies utilized cell viability assays, gene/protein expression analysis (PCR, Western blot), nitric oxide (NO) and reactive oxygen species (ROS) detection, and immunofluorescence.
• In vivo studies involved micro-CT scanning and histological staining (Safranin O-Fast Green, toluidine blue, immunohistochemistry) in an OA rat model.

Main Results:

• Avicularin inhibited ECM degradation and inflammation in chondrocytes by targeting TRAF6 and suppressing TRAF6/MAPK pathway activation.
• OA rats treated with avicularin showed reduced expression of MMP3 and MMP13, and increased levels of Aggrecan and Collagen II.
• Intra-articular avicularin injection attenuated OA-induced changes in vivo.

Conclusions:

• Avicularin demonstrates significant potential in suppressing OA-related cartilage degradation and inflammation.
• Targeting TRAF6 with avicularin presents a promising therapeutic strategy for osteoarthritis.
• Avicularin is identified as a potential therapeutic agent for managing osteoarthritis.